Sexual Health
PT-141
Bremelanotide's Vyleesi label covers a specific sexual-desire disorder in premenopausal women, not general sexual enhancement.
At a glance
Bremelanotide's Vyleesi label covers a specific sexual-desire disorder in premenopausal women, not general sexual enhancement.
PT-141, bremelanotide and Vyleesi
PT-141 is a name used for bremelanotide, a melanocortin receptor agonist. Vyleesi is the approved injectable drug product described in the cited FDA label. Approval of that product does not extend automatically to every vial or preparation marketed as PT-141.
The mechanism differs from drugs primarily affecting blood flow, but this does not make bremelanotide free of cardiovascular effects. The Vyleesi label contains blood-pressure warnings and important restrictions on who should receive it.
Sources: [vyleesi-label]
Who the approved indication covers
The cited label indicates Vyleesi for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). The low desire must cause marked distress or interpersonal difficulty and must not be due to a coexisting medical or psychiatric condition, relationship problems, or the effects of a medication or drug substance.
The label does not indicate it for postmenopausal women, men or enhancement of sexual performance. Low desire can have multiple causes; an evaluation matters because the approved indication excludes several of them.
Sources: [vyleesi-label]
What the clinical evidence does—and does not—show
The label describes two randomized, double-blind, placebo-controlled phase 3 trials in premenopausal women with HSDD. The main measures assessed changes in sexual desire and distress associated with low desire.
Improvements in those measured domains should not be interpreted as a general sexual-performance claim. The label reports no significant treatment difference in the change in the number of satisfying sexual events. Trial outcomes also do not establish effectiveness in populations excluded from the indication.
A benefit for an eligible study population does not predict an individual's response. Product-specific treatment decisions should consider the possible benefit alongside adverse effects, contraindications and alternative explanations for symptoms.
Sources: [vyleesi-label]
Blood pressure, nausea and other safety concerns
Vyleesi is contraindicated in uncontrolled hypertension or known cardiovascular disease. It can transiently increase blood pressure and decrease heart rate; the label advises assessment of cardiovascular risk before and during treatment.
Nausea is common: the cited label reports it in 40% of patients receiving up to eight monthly doses. Flushing, headache, vomiting and injection-site reactions also occur. Focal hyperpigmentation can affect areas including the face, gums and breasts, and resolution was not confirmed in some patients.
These are selected warnings, not the complete prescribing information. Pregnancy plans and any suspected pregnancy should be discussed with the prescriber. Severe or concerning symptoms should not be managed by changing an online dosing protocol.
Sources: [vyleesi-label]
Interactions and prescribing questions
Bremelanotide may slow gastric emptying and affect absorption of oral medicines. The label specifically advises avoiding use with oral naltrexone products intended to treat alcohol or opioid addiction because reduced exposure could undermine their effectiveness.
Review all medicines with the prescribing clinician, confirm the exact product, and ask how response and adverse effects will be assessed. This guide does not provide a personalized dosing schedule. Read the complete current label and follow the prescriber's instructions rather than treating research-product directions as a prescription.
Sources: [vyleesi-label]
Frequently asked questions
These FAQs use the sources listed below. They are not independently clinically reviewed.
How does PT-141 work?
Bremelanotide is a melanocortin receptor agonist. Its mechanism does not make it free of cardiovascular effects: the Vyleesi label warns of transient blood-pressure increases and lists uncontrolled hypertension or known cardiovascular disease as contraindications.
Sources: [vyleesi-label]
Is PT-141 FDA approved?
Vyleesi (bremelanotide) is approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women when not due to specified medical, relationship or drug causes. The cited label does not indicate it for men, postmenopausal women or enhancing sexual performance. This is not approval of every product marketed as PT-141.
Sources: [vyleesi-label]
Sources and reading notes
Sources support the cited sections or FAQs, not every statement in a legacy overview. A source link is not an endorsement of a product or treatment.
[vyleesi-label] U.S. Food and Drug Administration — Vyleesi (bremelanotide) prescribing information (2019)
The cited label specifies the approved population and cardiovascular warnings; consult the current label before treatment.
About this entry
Article updated: .
AI-assisted source synthesis prepared for Peptide Directory. No independent clinical review has been performed.